Trial Profile
A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD Surface Antigen, Inactivated, (Adjuvanted with MF59C.1) Influenza Vaccine, Formulation 2005-2006, when Administered to Elderly Subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jun 2011
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Therapeutic Use
- Sponsors Novartis
- 08 Jun 2011 Information from ClinicalTrials.gov record integrated.
- 08 Jun 2011 New trial record